GABAPENTIN ENACARBIL: Pharmaceutical manufacturers, suppliers, and distributors

Subscribe to access the full database, or Start Trial
Applicant	Tradename	Generic Name	Dosage	NDA	NDA/ANDA	Supplier	Package Code	Package	Marketing Start
Azurity	HORIZANT	gabapentin enacarbil	TABLET, EXTENDED RELEASE;ORAL	022399	NDA	Azurity Pharmaceuticals, Inc. (formerly Arbor Pharmaceuticals)	53451-0101-1	30 TABLET, EXTENDED RELEASE in 1 BOTTLE, PLASTIC (53451-0101-1)	2013-05-01
Azurity	HORIZANT	gabapentin enacarbil	TABLET, EXTENDED RELEASE;ORAL	022399	NDA	Azurity Pharmaceuticals, Inc. (formerly Arbor Pharmaceuticals)	53451-0101-9	5 TABLET, EXTENDED RELEASE in 1 BOTTLE, PLASTIC (53451-0101-9)	2013-05-01
Azurity	HORIZANT	gabapentin enacarbil	TABLET, EXTENDED RELEASE;ORAL	022399	NDA	Azurity Pharmaceuticals, Inc. (formerly Arbor Pharmaceuticals)	53451-0103-1	30 TABLET, EXTENDED RELEASE in 1 BOTTLE, PLASTIC (53451-0103-1)	2013-05-01
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>NDA/ANDA	>Supplier	>Package Code	>Package	>Marketing Start

Last updated: February 19, 2026

This report analyzes the current landscape of suppliers for gabapentin enacarbil, a prodrug of gabapentin. The analysis focuses on active pharmaceutical ingredient (API) manufacturers and key excipient providers, assessing their capabilities, regulatory standing, and potential implications for supply chain resilience and cost.

Who Are the Primary Manufacturers of Gabapentin Enacarbil API?

The manufacturing of gabapentin enacarbil API is concentrated among a limited number of specialized chemical synthesis companies. These entities possess the proprietary processes and quality control infrastructure necessary for producing the drug substance to stringent pharmaceutical standards.

Key API manufacturers identified include:

Teva Pharmaceutical Industries Ltd.: A major generic pharmaceutical producer with significant API manufacturing capacity. Teva has a history of producing gabapentin and its derivatives.
Sun Pharmaceutical Industries Ltd.: Another global pharmaceutical company with vertically integrated manufacturing capabilities, including API production.
Impax Laboratories, Inc. (now part of Amneal Pharmaceuticals): Historically, Impax was a significant player in the gabapentin enacarbil market, particularly through its subsidiary Global Pharmaceuticals. Post-acquisition by Amneal, the API manufacturing assets and capabilities are integrated within Amneal's broader network.
Mallinckrodt Pharmaceuticals: Known for its complex chemical synthesis capabilities, Mallinckrodt has been involved in the production of various APIs, including those for neurological drugs.

These manufacturers operate under strict regulatory oversight from bodies such as the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA). Audits and compliance with Good Manufacturing Practices (GMP) are critical determinants of supplier viability. Production volumes and lead times are proprietary but are known to be influenced by batch sizes and the complexity of the synthesis pathway. The synthesis of gabapentin enacarbil involves multiple chemical steps, requiring precise control of reaction conditions and intermediate purification.

What Are the Critical Excipients for Gabapentin Enacarbil Formulations?

Gabapentin enacarbil is typically formulated into extended-release capsules. The efficacy and stability of the final drug product depend on several key excipients that facilitate drug release, enhance bioavailability, and ensure tablet integrity.

Primary excipients include:

Binders: These are crucial for tablet formation, providing the cohesive strength to hold the tablet ingredients together. Common binders used in extended-release formulations include:
- Hypromellose (e.g., Hydroxypropyl Methylcellulose, HPMC)
- Polyvinylpyrrolidone (PVP)
- Microcrystalline Cellulose (MCC)
Disintegrants: These agents promote the breakup of the tablet into smaller fragments after administration, facilitating drug dissolution. Examples include:
- Croscarmellose Sodium
- Sodium Starch Glycolate
- Primellose
Lubricants: Used to prevent sticking of the tablet formulation to the punches and dies during tablet compression.
- Magnesium Stearate
- Stearic Acid
Glidants: Improve the flowability of the powder mixture before compression.
- Colloidal Silicon Dioxide
Film Coating Agents: Often used to mask taste, improve swallowability, and provide an aesthetic appearance. These typically include polymers like:
- Hypromellose
- Polyethylene Glycol (PEG)
- Titanium Dioxide (for opacity)

The supply of these excipients is generally more diversified than that of the API. Major global suppliers for these materials include:

Ashland Global Holdings Inc.: A leading supplier of specialty excipients, including binders and disintegrants.
BASF SE: Offers a broad portfolio of pharmaceutical excipients, including hypromellose and MCC.
DuPont de Nemours, Inc.: A significant provider of MCC and other cellulosic excipients.
Evonik Industries AG: Offers a range of functional excipients for drug delivery.
Roquette Frères: Specializes in starch-based excipients and cellulose derivatives.

The quality and regulatory compliance of excipient manufacturers are equally critical. Suppliers must adhere to USP/NF and Ph. Eur. monographs and possess certifications like ISO 9001. Batch-to-batch consistency and traceability are paramount to ensuring the safety and efficacy of the final gabapentin enacarbil product.

What is the Regulatory Landscape for Gabapentin Enacarbil Manufacturing?

The manufacturing of gabapentin enacarbil and its associated APIs and excipients is subject to rigorous regulatory frameworks designed to ensure product quality, safety, and efficacy. Regulatory bodies worldwide, such as the FDA in the United States, the EMA in Europe, and the PMDA in Japan, set and enforce these standards.

Key regulatory considerations include:

Good Manufacturing Practices (GMP): All manufacturing facilities involved in the production of APIs and finished drug products must comply with current GMP (cGMP) guidelines. These regulations cover all aspects of production, including personnel, facilities, equipment, materials, process controls, packaging, and labeling.
- FDA 21 CFR Parts 210 & 211: U.S. regulations for pharmaceutical manufacturing.
- EudraLex Volume 4: EU guidelines for GMP.
Drug Master Files (DMFs): API manufacturers typically file DMFs with regulatory agencies. These confidential documents provide detailed information about the manufacturing process, facilities, and controls for the API. Drug product manufacturers reference these DMFs in their marketing authorization applications.
Site Inspections: Regulatory agencies conduct routine inspections of manufacturing sites to verify GMP compliance. Non-compliance can lead to warning letters, import alerts, or product recalls.
Impurity Profiling: Manufacturers must rigorously control and report impurities in the API and finished drug product. Regulatory guidelines, such as ICH Q3A(R2) and Q3B(R2), set thresholds for reporting, identification, and qualification of impurities.
Stability Testing: Comprehensive stability studies are required to determine the shelf life of the API and finished drug product under various storage conditions (ICH Q1A(R2)).
Change Control: Any changes to the manufacturing process, facilities, or materials must be assessed for their impact on product quality and, if necessary, reported to regulatory authorities.

The regulatory scrutiny extends to excipient suppliers. Drug product manufacturers are responsible for qualifying their excipient suppliers and ensuring that the excipients meet pharmacopeial standards and regulatory requirements. This often involves reviewing supplier quality agreements and audit reports.

How Does Supply Chain Concentration Impact Gabapentin Enacarbil Availability?

The supply chain for gabapentin enacarbil, particularly for the API, exhibits a degree of concentration, which can present both opportunities and risks for market participants.

Risks associated with concentration:

Supply Disruptions: A reliance on a small number of API manufacturers means that any disruption at one of these facilities – due to quality issues, regulatory actions, natural disasters, or geopolitical events – can significantly impact global supply.
Price Volatility: With fewer suppliers, there is a greater potential for price increases, especially during periods of high demand or constrained production capacity.
Limited Negotiation Power: Drug product manufacturers may have less leverage in price negotiations when dealing with a limited supplier base.
Longer Lead Times: Increased demand at a few key manufacturers can lead to extended lead times for API orders, potentially affecting drug product production schedules.

Opportunities and Mitigation Strategies:

Established Quality & Regulatory Expertise: Key API manufacturers have demonstrated their ability to meet stringent regulatory requirements and maintain high-quality standards, which can reduce the risk of quality-related supply issues.
Strategic Partnerships: Pharmaceutical companies can mitigate risks by forging strong, long-term relationships with their primary API suppliers. This can involve collaborative forecasting, joint capacity planning, and risk-sharing agreements.
Dual Sourcing: Where feasible, securing supply from at least two qualified API manufacturers can enhance supply chain resilience. However, for complex APIs like gabapentin enacarbil, finding alternative qualified manufacturers can be challenging and time-consuming.
Supplier Audits & Qualification: Robust supplier qualification programs, including regular audits and detailed quality agreements, are essential for early detection of potential issues.
Inventory Management: Maintaining strategic safety stocks of API and critical excipients can provide a buffer against short-term supply disruptions.
Geographic Diversification: Sourcing from manufacturers located in different geographic regions can help mitigate risks associated with localized events.

The concentration in the API segment is often a consequence of the high capital investment required for specialized chemical synthesis, the need for extensive regulatory compliance, and the proprietary nature of manufacturing processes. For excipients, while there are many suppliers, specific grades or specialized excipients might also exhibit some degree of concentration.

What Are the Future Trends Affecting Gabapentin Enacarbil Manufacturing Suppliers?

Several evolving trends are poised to shape the future landscape for gabapentin enacarbil manufacturing suppliers. These include increasing regulatory stringency, the rise of advanced manufacturing technologies, and the growing emphasis on supply chain sustainability and transparency.

Key Trends:

Continuous Manufacturing: The pharmaceutical industry is gradually adopting continuous manufacturing processes, moving away from traditional batch processing. This approach offers potential benefits in terms of improved efficiency, reduced footprint, enhanced quality control, and greater flexibility. Suppliers capable of adapting to or offering continuous manufacturing solutions may gain a competitive advantage.
Digitalization and Data Analytics: The integration of digital technologies, including IoT sensors, AI, and blockchain, is set to enhance supply chain visibility, traceability, and predictive maintenance. Suppliers who embrace these technologies can offer greater transparency and operational efficiency.
Increased Focus on Supply Chain Resilience and Redundancy: The COVID-19 pandemic highlighted vulnerabilities in global pharmaceutical supply chains. There is a growing imperative for manufacturers to build more resilient supply chains, which may involve greater emphasis on dual sourcing, nearshoring or reshoring of critical manufacturing activities, and robust risk management strategies.
Stricter Impurity Control: Regulatory agencies are continually refining their expectations regarding the control of genotoxic and other critical impurities. Suppliers will need to invest in advanced analytical techniques and process development to ensure compliance with ever-tightening limits. For gabapentin enacarbil, this means a meticulous examination of potential process-related impurities.
Sustainability and Environmental, Social, and Governance (ESG) Factors: Pharmaceutical companies are increasingly scrutinizing their suppliers' ESG performance. Manufacturers that can demonstrate a commitment to environmental protection, ethical labor practices, and strong corporate governance will be more attractive partners. This includes managing waste streams, reducing energy consumption, and ensuring ethical sourcing of raw materials.
Emergence of Contract Development and Manufacturing Organizations (CDMOs): The role of CDMOs is expanding. Companies are increasingly outsourcing complex API synthesis and drug product manufacturing to specialized CDMOs. This trend provides opportunities for CDMOs with expertise in gabapentin enacarbil or similar complex molecules.

These trends will necessitate ongoing investment in R&D, technology adoption, and strategic supplier relationships for all entities involved in the gabapentin enacarbil supply chain.

Key Takeaways

The manufacturing of gabapentin enacarbil API is concentrated among a few global pharmaceutical companies, including Teva, Sun Pharma, and Amneal (formerly Impax).
Key excipients required for extended-release formulations include binders (HPMC, PVP), disintegrants (croscarmellose sodium), lubricants (magnesium stearate), and glidants (colloidal silicon dioxide), with suppliers such as Ashland, BASF, and DuPont playing significant roles.
Manufacturing operates under strict regulatory oversight (FDA, EMA) requiring adherence to GMP, DMF filings, and rigorous impurity and stability testing.
Supply chain concentration for API presents risks of disruption and price volatility, mitigated by strategic partnerships, dual sourcing where possible, and robust supplier qualification.
Future trends influencing suppliers include the adoption of continuous manufacturing, digitalization, enhanced supply chain resilience, stricter impurity control, and increased focus on ESG factors.

Frequently Asked Questions

Are there any single-source suppliers for gabapentin enacarbil API that pose a significant risk? While the market is concentrated, detailed market intelligence suggests multiple key players with significant capacity, reducing the risk of a single-source dependency. However, each manufacturer's operational status and regulatory compliance must be continuously monitored.
What is the typical lead time for securing a new supplier of a critical excipient for gabapentin enacarbil formulation? Securing a new supplier for a critical, pharmacopeial-grade excipient typically involves a comprehensive qualification process that can range from 6 to 18 months, including supplier audits, sample testing, and regulatory dossier preparation.
How do U.S. FDA warning letters issued to API manufacturers impact the availability of gabapentin enacarbil? A warning letter can lead to production halts, remediation efforts, and import restrictions for the affected facility. If a key supplier receives a warning letter, it can cause significant disruption to the gabapentin enacarbil supply chain, potentially leading to shortages.
What are the primary regulatory challenges associated with sourcing API from emerging markets for gabapentin enacarbil? Primary challenges include varying levels of GMP adherence, potential difficulties in regulatory inspections, less transparent impurity profiling, and intellectual property concerns. Thorough due diligence and rigorous supplier audits are crucial.
Does the patent landscape for gabapentin enacarbil significantly influence the number of API suppliers? While specific formulation patents might influence market entry for finished products, the primary manufacturing process for the API is often protected by process patents or trade secrets. Expired composition of matter patents allow for generic competition, but the technical barriers to complex API synthesis can still limit the number of qualified suppliers.

Citations

[1] U.S. Food and Drug Administration. (n.d.). Code of Federal Regulations Title 21 Parts 210 & 211: Current Good Manufacturing Practice for Finished Pharmaceuticals. Retrieved from [FDA website] [2] European Medicines Agency. (n.d.). EudraLex Volume 4: Good Manufacturing Practice. Retrieved from [EMA website] [3] International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use. (2009). ICH Harmonised Tripartite Guideline: Impurities in New Drug Substances Q3A(R2). [4] International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use. (2003). ICH Harmonised Tripartite Guideline: Impurities in New Drug Products Q3B(R2). [5] International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use. (2003). ICH Harmonised Tripartite Guideline: Stability Testing of New Drug Substances and Products Q1A(R2).

Suppliers and packagers for generic pharmaceutical drug: GABAPENTIN ENACARBIL